Dr Andrew Thomas 
Senior Lecturer

Cardiff School of Health Sciences
University of Wales Institute Cardiff, 
CF5 2YB. 

tel +44 (0)29 20416844
fax +44 (0)29 20416982
email: athomas@uwic.ac.uk

B.Sc Hons (Tech) 1986 PhD (Wales) 1990 
P.G.C.E. (FE) 1992 

Previous employment

1993-1997 Postdoctoral Research Fellow, University of Wales College of Medicine

1990-1991 Project Manager, British BioCell International Cardiff 
1984-1985 Research Technician, Cadbury Schweppes (Group Research) CAMR/PHLS, Salisbury 

Molecular biology, genetics, cell biology, biotechnology, pharmacology. Research methods, ethics.

University Responsibilities
Member of Research and Enterprise Board

Member of School of Applied Science Ethics Panel

Member of Genetic Manipulation Advisory Panel

Research Student Supervision
Current Students
Maninder Alhuwalia
Thet Thet Lin
Stephen Potter

PhD Completions
Al-Ketheree Nasser Zainab (2004) Rapid diagnositic test for salicytate sensitivity.

External Responsibilities
Director of Allergenix Limited.

Reviewer of scientific journals, AVTB and Diabetic Medicine.

Other Responsibilities
Supervision of MD research degree students
Internal examination of Ph.D students

Research Interests: 
In general, my research interests have concentrated on the genetic basis of type 2 diabetes and the molecular mechanisms involved in the accelerated atherosclerosis that is associated with diabetes. Specifically, I am interested in the role of hyperglycaemia and advanced glycated end-products (AGEs), and their respective receptor (AGER), in the development and stability of atherosclerotic lesions.  I am also interested in the way in which PPAR gamma ligands (both synthetic and natural) and exercise can modulate intracellular signalling cascades, alter gene expression and ultimately interfere with the atherosclerotic and inflammatory pathways that are central to the pathological complications associated type 2 diabetes. The overall outcome of this research is to elucidate the beneficial molecular effects that drug intervention, alteration of diet and increased physical activity can have on insulin resistance and diabetes-associated atherosclerosis.

Butcher, L., Backx, K., Roberts, A., Thomas, A.W, Webb, R., and Morris, K. (2008) Low-intensity exercise, LDL oxidation and regulation of lipoprotein clearance genes. Med. Sci. Sports. Ex. 40 (7):1–7.

Caddy, J., Singh, N., Atkin, L., Ahluwalia, M., Roberts, A.W., Lang, D., Thomas, A.W. and Webb, R. (2008) Rosiglitazone Transiently Disturbs Calcium Homeostasis in Monocytic Cells Biochem. Biophys. Res. Comm. 366:149-155.

Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM (2008) .Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 197(2):718-24.

Morris RH, Tonks AJ, Jones KP, Ahluwalia MK, Thomas AW, Tonks A, Jackson SK 2008. DPPC regulates COX-2 expression in monocytes via phosphorylation of CREB2008. Biochem Biophys Res Commun. 370(1):174-8.

O.E. Okosieme, A.B. Parkes, L.D.K.E. Premawardhana, A.W. Thomas, L.M. Evans, J.H. Lazarus (2006) Peripheral Cytokine Expression in Autoimmune Thyroiditis: Effects of In Vitro Modulation by Rosiglitazone and Dexamethasone. Thyroid. 16 (10) : 953-960

Singh N, Webb R, Adams R, Evans S-A, Al-Mosawi A, Evans M, Roberts AW and Thomas AW. (2005) The PPAR gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: Involvement of Akt and intracellular calcium. Biochemical and Biophysical Research Communication 333: 455-462.

Roberts AW, Thomas AW, Evans M, Rees A. (2003) Peroxisome Proliferator-activated Receptor gamma agonists in atherosclerosis: Current Evidence and Future Directions.  Current Opinions in Lipidology 14(6): 567-573

Evans M, Anderson RA, Smith JC, Khan N, Graham JM, Thomas AW, Morris K, Deely D, Frenneaux MP, Davies JS and Rees A. (2003) Effects of insulin lispro and chronic vitamin C therapy on postprandrial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Eur. J. Clin. Invest. 33(3): 231-238.

Weightman AJ, Topping AW, Hill KE, Lee L, Sakai K, Slater JH, and Thomas AW (2002) Transposition of DEH, a Broad-Host-Range Transposon Flanked by ISPpu12, in Pseudomonas putida is Associated with Genomic Rearrangements and Dehalogenase Gene Silencing. J Bacteriol 184(23):6581-91

Ahluwalia M, Evans M, Morris K, Currie C, Davies, A, Rees A and Thomas AW (2002) The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 4:1-3.

Gill-Randall R, Sherratt EJ, Thomas AW, Gagg JW, Lee A, Alcolado JC. (2001)
Analysis of a polycytosine tract and heteroplasmic length variation in the mitochondrial DNA D-loop of patients with diabetes, MELAS syndrome and race-matched controls. Diabetic Medicine 18(5):413-416.

Tonks A,  Morris RHK, Price A.J, Thomas AW, Jones KP and Jackson SK. (2001) Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases. Cellular Immunology 124(1):86-94

Sherratt E, Thomas AW, Gagg J, Majid A, and Alcolado J. (1999) Mitochondrial DNA variations in patients with Type 2 (non-insulin dependent) diabetes mellitus and a Welsh control population. Human  Mutation. 13(5): 412-413 (on line citation http//journal.wiley.com/1059-7794/mutbr1.html).

Thomas AW, Sherratt E, Majid A, Gagg J and Alcolado J. (1999) Differential expression of mRNA in human thyroid cells depleted of mitochondrial DNA by ethidium bromide treatment. Clinical Science 97: 207-213.

Sherratt E, Thomas AW, Gill-Randerson R, Alcolado J.(1999) Phylogenetic analysis of mitochondrial DNA in type 2 diabetes: Maternal history and ancient population expansion. Diabetes 48:628-634

Thomas AW, Sherratt E, Majid A, Gagg J, Davies SA and Alcolado J. (1997) Genetic linkage study of a major susceptibility locus (D2S125) in a British population of non-insulin dependent diabetic sib-pairs using a simple non-isotopic screening method. Human Genetics 101:212-213.

Sherratt E, Thomas AW, and Alcolado J. (1997) Mitochondrial gene defects: A widening spectrum of clinical disorders. Clinical Science 92:225-235.

Sherratt E, Thomas AW, Gagg J and Alcolado J. (1996) Non-radioactive characterisation of low level heteroplasmic mitochondrial DNA mutations by single-stranded conformational polymorphism (SSCP)-PCR enrichment. BioTechniques 20(3): 430-432.

Thomas AW, Edwards A, Majid A, Gagg J, Morgan R, Rees A and Alcolado J. (1996) Molecular scanning of candidate mitochondrial tRNA genes in type 2 (non-insulin dependent) diabetes mellitus. Journal of Medical Genetics 33: 253-255.

Topping AW, Thomas AW, Slater JH and Weightman AJ (1995) The nucleotide sequence of a transposable haloalkanoic acid dehalogenase regulatory gene (dehRI) from Pseudomonas putida strain PP3 and its relationship with 54-dependent activators. Biodegradation 6: 247-255.

Alcolado JC and Thomas AW  (1995) Maternally inherited diabetes mellitus: the role of mitochondrial DNA defects. Diabetic Medicine 12: 102-108.

Thomas AW, Morgan R, Sweeney M, Rees A and Alcolado J (1994) The detection of mitochondrial DNA mutations using SSCP and heteroduplex analysis. Human Genetics. 94: 621-623.

Thomas AW, Lewington J, Hope S, Topping AW, Weightman AJ and Slater JH (1993) Environmentally directed mutations in the dehalogenase system of Pseudomonas putida PP3. Archives of Microbiology. 158: 176-182.

Thomas AW, Slater JH and Weightman AJ (1992) The dehalogenase gene dehI from Pseudomonas putida PP3 is carried on an unusual genetic element designated DEH. J. Bact. 174: 1932-1940.

Thomas AW, Topping AW, Slater JH and Weightman AJ (1992) Localisation and functional analysis of structural and regulatory dehalogenase genes carried on DEH from Pseudomonas putida PP3. J. Bact. 174: 1941-1947.